(1R,2S)-2-[[(2,4-Dimethyl-5-pyrimidinyl)oxy]methyl]-2-(3-fluorophenyl)-N-(5-fluoro-2-pyridinyl)cyclopropanecarboxamide - Names and Identifiers
(1R,2S)-2-[[(2,4-Dimethyl-5-pyrimidinyl)oxy]methyl]-2-(3-fluorophenyl)-N-(5-fluoro-2-pyridinyl)cyclopropanecarboxamide - Physico-chemical Properties
Molecular Formula | C22H20F2N4O2
|
Molar Mass | 410.4166 |
Density | 1.347±0.06 g/cm3(Predicted) |
Melting Point | 173 - 175°C |
Boling Point | 596.1±50.0 °C(Predicted) |
Solubility | DMSO: ≥ 30 mg/mL |
Appearance | Form Solid, color White to Off-White |
pKa | 12.30±0.40(Predicted) |
Storage Condition | -20°C, Inert atmosphere |
Use | The lemborexant of use is a dual inhibitor of OX1 and OX2 receptors, discovered and developed by Eisai. The compound inhibits orexin by competitively binding to 2 subtypes of orexin receptors (orexin receptor 1 and receptor 2). |
(1R,2S)-2-[[(2,4-Dimethyl-5-pyrimidinyl)oxy]methyl]-2-(3-fluorophenyl)-N-(5-fluoro-2-pyridinyl)cyclopropanecarboxamide - Preparation solution concentration reference
| 1mg | 5mg | 10mg |
---|
1 mM | 2.437 ml | 12.183 ml | 24.365 ml |
5 mM | 0.487 ml | 2.437 ml | 4.873 ml |
10 mM | 0.244 ml | 1.218 ml | 2.437 ml |
5 mM | 0.049 ml | 0.244 ml | 0.487 ml |
Last Update:2024-01-02 23:10:35
(1R,2S)-2-[[(2,4-Dimethyl-5-pyrimidinyl)oxy]methyl]-2-(3-fluorophenyl)-N-(5-fluoro-2-pyridinyl)cyclopropanecarboxamide - Nature
solubility |
DMSO (Slightly), Methanol (Slightly) |
Last Update:2024-04-10 22:29:15
(1R,2S)-2-[[(2,4-Dimethyl-5-pyrimidinyl)oxy]methyl]-2-(3-fluorophenyl)-N-(5-fluoro-2-pyridinyl)cyclopropanecarboxamide - Application
lemborexant interfere with orexin neurotransmission and purposeful promotion of sleep initiation and maintenance. At present, Aisai is cooperating with Purdue to develop lemborexant for the treatment of various sleep disorders.
Last Update:2024-04-10 22:29:15